CancerSeq™ FFPE tissues from AMSBIO are pre-screened tumor tissue samples for single nucleotide polymorphisms (SNP’s), insertions and deletions plus copy number variations (CNVs) using targeted Next Generation Sequencing to identify key mutations.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), announced updates on its oncology assay portfolio and regulatory milestones, ahead of its presence at the AMP 2024 meeting.

Transgene and ProBioGen, announce that the companies have entered into a license agreement for ProBioGen’s AGE1.CR.pIX® suspension cell line.

Alfa Chemistry is delighted to announce the launch of its much-anticipated Scholarship Program 2024, aimed at supporting and empowering chemistry-related college students.

Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced progress within the Company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline.

Top line data show that the randomized Phase II study of TG4001 in combination with avelumab versus avelumab in patients with recurrent or metastatic HPV16-positive cervical and anogenital tumors did not meet the primary objective of improvement.